Discounting in the evaluation of the cost-effectiveness of a vaccination programme: A critical review.

[1]  John Appleby,et al.  A Terrible Beauty: A short history of NICE the National Institute for Health and Care Excellence , 2017 .

[2]  M. Postma,et al.  Differential Time Preferences for Money and Quality of Life , 2014, PharmacoEconomics.

[3]  W. John Edmunds,et al.  Assessing Optimal Target Populations for Influenza Vaccination Programmes: An Evidence Synthesis and Modelling Study , 2013, PLoS medicine.

[4]  D. Pieper,et al.  Methods of international health technology assessment agencies for economic evaluations- a comparative analysis , 2013, BMC Health Services Research.

[5]  Mike Paulden,et al.  NICE's selective application of differential discounting: ambiguous, inconsistent, and unjustified. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[6]  M. Postma,et al.  Economic evaluation of vaccines: specificities and future challenges illustrated by recent European examples , 2013, Expert review of vaccines.

[7]  M. Jit,et al.  Economic Evaluations of Childhood Influenza Vaccination , 2012, PharmacoEconomics.

[8]  M. Postma,et al.  Discounting health effects in pharmacoeconomic evaluations , 2012, PharmacoEconomics.

[9]  Gustav Tinghög,et al.  Discounting, Preferences, and Paternalism in Cost-Effectiveness Analysis , 2012, Health Care Analysis.

[10]  M. Postma,et al.  On discounting of health gains from human papillomavirus vaccination: effects of different approaches. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[11]  Mathias W Pletz,et al.  Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany , 2012, Health Economics Review.

[12]  A. Melegaro,et al.  The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom. , 2012, Vaccine.

[13]  J. Habbema,et al.  Practical implications of differential discounting in cost-effectiveness analyses with varying numbers of cohorts. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[14]  T. Taylor,et al.  Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries. , 2010, Vaccine.

[15]  Marco Casari,et al.  On Negative Time Preference , 2010 .

[16]  R. Hutubessy,et al.  WHO Guide for standardisation of economic evaluations of immunization programmes. , 2010, Vaccine.

[17]  A. Miners,et al.  Economic evaluations of Haemophilus influenzae type b vaccine: systematic review of the literature , 2009, Expert review of pharmacoeconomics & outcomes research.

[18]  M. Boily,et al.  Economic Evaluation of Human Papillomavirus Vaccination in Developed Countries , 2009, Public Health Genomics.

[19]  A. Rothberg.  Making Choices in Health: WHO Guide to Cost Effectiveness Analysis , 2008 .

[20]  P. Mathevet,et al.  Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France , 2008, International Journal of Technology Assessment in Health Care.

[21]  M. Drummond,et al.  Do we fully understand the economic value of vaccines? , 2007, Vaccine.

[22]  P. van Damme,et al.  Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination--a review (2002-2006). , 2007, Vaccine.

[23]  John Cairns,et al.  Developments in discounting: With special reference to future health events , 2006 .

[24]  M. Postma,et al.  Need for differential discounting of costs and health effects in cost effectiveness analyses , 2005, BMJ : British Medical Journal.

[25]  A. Rothberg.  Making Choices in Health : WHO Guide to Cost Effectiveness Analysis, edited by T. Tan-Torres Edejer, R. Baltussen, T. Adam, R. Hutubessy, A. Acharya, D.B. Evans and C.J.L. Murray : book review , 2004 .

[26]  Jeff Richardson,et al.  The rule of rescue. , 2003, Social science & medicine.

[27]  M. Bigham,et al.  Modelling the costs and effects of a universal infant immunization program using conjugated pneumococcal vaccine in British Columbia. , 2003, Canada communicable disease report = Releve des maladies transmissibles au Canada.

[28]  T. Duke.  Haemophilus influenzae type b meningitis: how much better is prevention than cure? , 2002, Papua and New Guinea medical journal.

[29]  G. Loewenstein,et al.  Time Discounting and Time Preference: A Critical Review , 2002 .

[30]  R. Barberán,et al.  The economic evaluation of health programmes: why discount health consequences more than monetary consequences? , 2002 .

[31]  H. Gravelle,et al.  Discounting for health effects in cost-benefit and cost-effectiveness analysis. , 2001, Health economics.

[32]  Han Bleichrodt,et al.  Time Preference for Health: A Test of Stationarity versus Decreasing Timing Aversion. , 2001, Journal of mathematical psychology.

[33]  E. Birnie,et al.  The discount rate in the economic evaluation of prevention: a thought experiment , 2001, Journal of epidemiology and community health.

[34]  M. Usher,et al.  The United Kingdom , 2001, Migration and Integration.

[35]  W. Brouwer,et al.  A Fair Approach to Discounting Future Effects: Taking a Societal Perspective , 2000, Journal of health services research & policy.

[36]  J. Cairns,et al.  Negative and zero time preference for health. , 2000, Health economics.

[37]  J. Carlin,et al.  Cost effectiveness of rotavirus vaccination in Australia , 1999, Australian and New Zealand journal of public health.

[38]  V. Nguyen,et al.  Discounting: technical issues in economic evaluations of vaccination. , 1999, Vaccine.

[39]  Ben A. van Hout,et al.  Discounting costs and effects: a reconsideration. , 1998 .

[40]  C. Murray,et al.  Understanding DALYs (disability-adjusted life years). , 1997, Journal of health economics.

[41]  Martin Ahlbrecht,et al.  An empirical study on intertemporal decision making under risk , 1997 .

[42]  David I. Laibson,et al.  Golden Eggs and Hyperbolic Discounting , 1997 .

[43]  M. Johannesson,et al.  The discounting of lives saved in future generations--some empirical results. , 1996, Health economics.

[44]  J. Cairns,et al.  Valuing future benefits. , 1994, Health economics.

[45]  A. Gafni,et al.  Discounting in the Economic Evaluation of Health Care Interventions , 1993, Medical care.

[46]  G. Loewenstein,et al.  Anomalies in Intertemporal Choice: Evidence and an Interpretation , 1992 .

[47]  J Lipscomb,et al.  Time Preference for Health in Cost-Effectiveness Analysis , 1989, Medical care.

[48]  William Samuelson,et al.  Status quo bias in decision making , 1988 .

[49]  A. Baier,et al.  Reasons and Persons , 1984 .

[50]  D. Cohen.  Utility model of preventive behaviour. , 1984, Journal of epidemiology and community health.

[51]  E. Keeler,et al.  Discounting of Life-Saving and Other Nonmonetary Effects , 1983 .

[52]  M. Weinstein,et al.  Foundations of cost-effectiveness analysis for health and medical practices. , 1977, The New England journal of medicine.

[53]  R. Nelson,et al.  American economic association (k1). , 1966, Science.

[54]  P. Samuelson.  A Note on Measurement of Utility , 1937 .

[55]  F. Ramsey,et al.  THE MATHEMATICAL THEORY OF SAVING , 1928 .

[56]  L. Garattini,et al.  Cost Effectiveness of the New Pneumococcal Vaccines: A Systematic Review of European Studies , 2013, PharmacoEconomics.

[57]  P. Beutels,et al.  Reviewing the Cost Effectiveness of Rotavirus Vaccination , 2012, PharmacoEconomics.

[58]  B. Cohen.  Discounting in Cost-Utility Analysis of Healthcare Interventions , 2012, PharmacoEconomics.

[59]  Sun-Young Kim,et al.  Cost-Effectiveness Analyses of Vaccination Programmes , 2012, PharmacoEconomics.

[60]  Stuart Birks,et al.  Discounting Health Effects in Pharmacoeconomic Evaluations: Current Controversies , 2012, PharmacoEconomics.

[61]  A. Culyer,et al.  Discounting and decision making in the economic evaluation of health-care technologies. , 2011, Health economics.

[62]  Sue J Goldie,et al.  Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches. , 2008, PharmacoEconomics.

[63]  Karl Claxton,et al.  Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion. , 2006, Health economics.

[64]  M. Postma,et al.  Discounting health effects in pharmacoeconomic evaluations: current controversies. , 2005, PharmacoEconomics.

[65]  M. Postma,et al.  Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases. , 2004, PharmacoEconomics.

[66]  農林水産奨励会農林水産政策情報センター,et al.  The green book : appraisal and evaluation in central government , 2003 .

[67]  H. Glick,et al.  Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. , 2002, PharmacoEconomics.

[68]  B. van Hout.  Discounting costs and effects: a reconsideration. , 1998, Health economics.

[69]  C. Harvey.  The reasonableness of non-constant discounting , 1994 .

[70]  D. Prelec,et al.  Negative Time Preference , 1991 .

[71]  F. Fenner.  Smallpox and its eradication , 1988 .